Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: A randomized, double-blind, placebo-controlled study

International Journal of Obesity

Volumn 31, Issue 1, 2007, Pages 138-146

  Toplak, H ^a,g   Hamann, A ^b   Moore, R ^c   Masson, E ^d   Gorska, M ^e   Vercruysse, F ^f   Sun, X ^f   Fitchet, M ^f  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c Centre for Diabetes and Endocrinology   (South Africa)

^d HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^e MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^f JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^g Diabetes and Metabolism   (Austria)

Author keywords

Metformin; Topiramate; Type 2 diabetes

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; METFORMIN; PLACEBO; TOPIRAMATE;

ADULT; AGED; ANOREXIA; ARTICLE; ATTENTION; BACKACHE; BEHAVIOR MODIFICATION; BICARBONATE BLOOD LEVEL; BLEEDING; BODY WEIGHT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIET; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENERGY EXPENDITURE; EXERCISE; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPESTHESIA; HYPOGLYCEMIA; KIDNEY FAILURE; LEUKOPENIA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MENTAL CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PAIN; PARESTHESIA; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; TASTE DISORDER; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FRUCTOSE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; OBESITY; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 33845750696     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803382     Document Type: Article

References (34)

1. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17: 961-969.
2. Colditz GA, Willett WC, Rotnitsky A, Manson JE. Weight gain as a risk factor for clinical diabetes in women. Ann Intern Med 1995; 122: 481-486.
3. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790-797.
4. Resnick HE, Valsania P, Halter JB, Lin X. Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults. J Epidemiol Commun Health 2000; 54: 596-602.
5. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al., for the Finish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
6. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 303-403.
7. Wing RR, Koeske R, Epstein LH, Nuwalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetes patients. Arch Intern Med 1987; 147: 1749-1753.
8. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Dis 1992; 16: 397-415.
9. Mertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res 2000; 8: 270-278.
10. Blacket RB, Leelarthaepin B, McGilchrist CA, Palmer AJ, Woodhill JM. The synergistic effect of weight loss and changes in dietary lipids on the serum cholesterol of obese men with hypercholesterolemia: implications for prevention of coronary heart disease. Aust NZ J Med 1979; 9: 521-529.
11. Davis TA, Anderson EC, Ginsburg AV, Goldberg AP. Weight loss improved lipoprotein lipid profiles in patients with hypercholesterolemia. J Lab Clin Med 1985; 106: 447-454.
12. Centers for Disease Control and Prevention. Diabetes: disabling, deadly, and on the rise - 2003. Available at http://www.cdc.gov/nccdphp/aag/aag_ddt.htm. Accessed 9 February 2004.
13. American Diabetes Association. Clinical Practice Recommendations 2005. Diabetes Care 2005; 28 (suppl 1): S1-S79.
14. Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. Diabetes Care 2004; 27: 2067-2073.
15. Hermann LS, Schersten B, Bitzen PO, Kjellstrom T, Lindgarde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care 1994; 17: 1100-1109.
16. Johansen K. Efficacy of metformin in the treatment of NIDDM: meta-analysis. Diabetes Care 1999; 22: 33-37.
17. Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabetes Metab 1991; 17: 224-231.
18. Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a six month dose ranging study. Orlistat Dose Ranging Study Group. Eur J Clin Pharmacol 1998; 54: 125-132.
19. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition 2000; 16: 961-966.
20. Richard D, Picard F, Lemieux C, Lalonde J, Samson P, Deshaies Y. The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord 2002; 26: 344-353.
21. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM et al. Sibutramine produces dose-related weight loss. Obes Res 1999; 7: 189-198.
22. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M, OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004; 28: 1399-1410.
23. Astrup A, Caterson I, Zelissen P, Guy-Grand B, Carruba M, Levy B et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004; 12: 1658-1669.
24. WHO. Energy and protein requirements: report of a joint FAO/WHO/UNU expert consultation. WHO:Geneva, 1985. Technical report series no. 72471.
25. Dubey SD. Adjustment of P-values for multiplicities of intercorrelating symptoms. In: Buncher RC, Tsay JY (eds). Statistics in the Pharmaceutical Industry. 2nd edn. Marcel Dekker Inc: New York, 1994, pp 513-527.
26. Lean MEJ, Powrie JK, Anderson JS, Carthwaite PH. Obesity, weight loss, and prognosis in type 2 diabetes. Diabetes Med 1998; 7: 228-233.
27. Wing RR, Marcus MD, Epstein LH, Salata R. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987; 10: 563-566.
28. Guare JC, Wing RR, Grant A. Comparison of obese NIDDM and nondiabetic women: short- and long-term weight loss. Obes Res 1995; 3: 329-335.
29. Finer N. Pharmacotherapy of obesity. Best Pract Res Clin Endocrinol Metab 2002; 16: 717-742.
30. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GAGA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsia 1997; 28: 167-179.
31. Gibbs 3rd JS, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000; 41 (Suppl 1): S10-S16.
32. Taverna S, Sancini G, Mantagazza M, Franceschetti S, Avanzini G. Inhibition of transient and persistent Na+ fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther 1999; 288: 960-968.
33. York DA, Singer L, Thomas S, Bray GA. Effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 2000; 16: 967-975.
34. Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: Where do we go from here? Science 2003; 299: 853-855.